Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 3;102(4):749–754. doi: 10.1007/s00277-023-05109-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© ©The Author(s) 2023 2023, corrected publication 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — Kaplan–Meier analysis of OS and RFS in propensity-score matched patients with and without censoring at HSCT. A OS in all patients. B OS in patients after censoring at HSCT^a. C RFS in all patients. D RFS in patients after censoring at HSCT^b. ^aA total of 30 patients treated with IC and 12 treated with VEN-AZA were censored at HSCT. ^bFor this comparison, 25 patients treated with IC and 12 with VEN-AZA were censored at HSCT. HSCT, hematopoietic stem cell transplant; IC, intensive chemotherapy; OS, overall survival; RFS, relapse-free survival; VEN-AZA, venetoclax plus azacitidine combination therapy